{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:21:07Z","timestamp":1793852467104,"version":"4.6.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007136","name":"Karyopharm Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007136","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01571-2","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T19:59:37Z","timestamp":1784577577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Single agent selinexor is active in patients with myelofibrosis refractory or intolerant to JAK inhibitors"],"prefix":"10.1038","volume":"16","author":[{"given":"Srinivas K.","family":"Tantravahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea A.","family":"Ellero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brynn","family":"Parsegov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey T.","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth M.","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton V.","family":"Rets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8019-2940","authenticated-orcid":false,"given":"Josef T.","family":"Prchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2987-1331","authenticated-orcid":false,"given":"Michael W.","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"1571_CR1","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1182\/blood.2022017423","volume":"141","author":"F Passamonti","year":"2023","unstructured":"Passamonti F, Mora B. Myelofibrosis. Blood. 2023;141:1954\u201370.","journal-title":"Blood"},{"key":"1571_CR2","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799\u2013807.","journal-title":"N Engl J Med"},{"key":"1571_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/ajh.27659","volume":"100","author":"N Gangat","year":"2025","unstructured":"Gangat N, Tefferi A. Emerging pathogenetic mechanisms and new drugs for anemia in myelofibrosis and myelodysplastic syndromes. Am J Hematol. 2025;100:51\u201365.","journal-title":"Am J Hematol"},{"key":"1571_CR4","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1016\/S2352-3026(23)00305-8","volume":"11","author":"N Kr\u00f6ger","year":"2024","unstructured":"Kr\u00f6ger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, Griesshammer M, et al. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT\/ELN International Working Group. Lancet Haematol. 2024;11:e62\u2013e74.","journal-title":"Lancet Haematol"},{"key":"1571_CR5","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1158\/1078-0432.CCR-18-0959","volume":"25","author":"D Yan","year":"2019","unstructured":"Yan D, Pomicter AD, Tantravahi S, Mason CC, Senina AV, Ahmann JM, et al. Nuclear-cytoplasmic transport is a therapeutic target in myelofibrosis. Clin Cancer Res. 2019;25:2323\u201335.","journal-title":"Clin Cancer Res"},{"key":"1571_CR6","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1182\/blood.2024025802","volume":"144","author":"A Tefferi","year":"2024","unstructured":"Tefferi A, Barosi G, Passamonti F, Hernandez-Boluda JC, Bose P, D\u00f6hner K, et al. Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosis. Blood. 2024;144:1813\u201320.","journal-title":"Blood"},{"key":"1571_CR7","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29:1356\u201363.","journal-title":"J Clin Oncol"},{"key":"1571_CR8","doi-asserted-by":"publisher","first-page":"5835","DOI":"10.1182\/bloodadvances.2023010151","volume":"7","author":"ST Oh","year":"2023","unstructured":"Oh ST, Mesa RA, Harrison CN, Bose P, Gerds AT, Gupta V, et al. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv. 2023;7:5835\u201342.","journal-title":"Blood Adv"},{"key":"1571_CR9","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1182\/bloodadvances.2020002662","volume":"4","author":"ST Oh","year":"2020","unstructured":"Oh ST, Talpaz M, Gerds AT, Gupta V, Verstovsek S, Mesa R, et al. ACVR1\/JAK1\/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Adv. 2020;4:4282\u201391.","journal-title":"Blood Adv"},{"key":"1571_CR10","doi-asserted-by":"publisher","first-page":"e729","DOI":"10.1016\/S2352-3026(24)00212-6","volume":"11","author":"CN Harrison","year":"2024","unstructured":"Harrison CN, Mesa R, Talpaz M, Al-Ali HK, Xicoy B, Passamonti F, et al. Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Haematol. 2024;11:e729\u2013e740.","journal-title":"Lancet Haematol"},{"key":"1571_CR11","doi-asserted-by":"publisher","first-page":"5825","DOI":"10.1182\/bloodadvances.2020003314","volume":"4","author":"AT Gerds","year":"2020","unstructured":"Gerds AT, Savona MR, Scott BL, Talpaz M, Egyed M, Harrison CN, et al. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. Blood Adv. 2020;4:5825\u201335.","journal-title":"Blood Adv"},{"key":"1571_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","volume":"401","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Lancet. 2023;401:269\u201380.","journal-title":"Lancet"},{"key":"1571_CR13","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1200\/JCO.20.02864","volume":"39","author":"J Mascarenhas","year":"2021","unstructured":"Mascarenhas J, Komrokji RS, Palandri F, Martino B, Niederwieser D, Reiter A, et al. Randomized, single-blind, multicenter phase ii study of two doses of imetelstat in relapsed or refractory myelofibrosis. J Clin Oncol. 2021;39:2881\u201392.","journal-title":"J Clin Oncol"},{"key":"1571_CR14","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/s41591-025-03572-3","volume":"31","author":"RK Rampal","year":"2025","unstructured":"Rampal RK, Grosicki S, Chraniuk D, Abruzzese E, Bose P, Gerds AT, et al. Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial. Nat Med. 2025;31:1531\u20138.","journal-title":"Nat Med"},{"key":"1571_CR15","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1182\/bloodadvances.2025018706","volume":"10","author":"H Ali","year":"2026","unstructured":"Ali H, Mohan SR, Kishtagari A, Prchal JT, Maher K, Chai Y, et al. Selinexor plus ruxolitinib in JAK inhibitor-na\u00efve patients with myelofibrosis: a multicenter, open-label, phase 1 study. Blood Adv. 2026;10:3383\u201397.","journal-title":"Blood Adv"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01571-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01571-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01571-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T19:59:37Z","timestamp":1784577577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01571-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1571"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01571-2","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"30 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SKT reports consulting for Novartis, GSK, Karyopharm Therapeutics, Sobi, BMS, and TERN Pharmaceuticals, and research support from Karyopharm Therapeutics. AAE and CJW are employees of Karyopharm Therapeutics. AVR reports consulting for Blueprint Medicines (Sanofi). MWD reports consulting for Novartis, Takeda, Blueprint and Cogent. ABP, BP, JTY, KMB, and JTP report no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was conducted in accordance with all relevant institutional guidelines and regulations. The study protocol was approved by the University of Utah Institutional Review Board (IRB_00114354; approved February 2024). All participants provided written informed consent prior to inclusion in the study.","order":2,"name":"Ethics","label":"Ethics aproval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"120"}}